03-17-2005: Sigma-Aldrich Corporation has entered into an agreement with the Massachusetts Institute of Technology (MIT) to serve as a scientific collaborator and distribution partner of The RNAi Consortium (TRC). The consortium is based at The Broad Institute in Boston and is comprised of seven world-class research institutions and four commercial partners. Over the next three years, this consortium's goal is to create a comprehensive library of RNA Interference (RNAi) reagents designed to reduce expression of specific human and mouse genes thereby enabling scientists to elucidate the function of the targeted gene. In addition to participating as a sponsoring member of the consortium, Sigma-Aldrich will commercially distribute clones, purified DNA and viral stocks from the RNAi libraries, facilitating their use by researchers worldwide.
The consortium involves scientific collaborations between principal investigators at seven research institutions: Massachusetts General Hospital, Harvard Medical School, Dana-Farber Cancer Institute, The Broad Institute, Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology and Academia Sinica. In addition to Sigma-Aldrich, TRC also includes corporate partners Bristol-Myers Squibb, Eli Lilly and Novartis.
"These 11 world-class entities will make common cause in a unique collaborative group to create a public good: a comprehensive set of reagents to be used in thousands of laboratories," said Dr. Eric S. Lander, Director of the Broad Institute and one of TRC's principal investigators. "In addition, the organizations will each benefit from sharing their expertise to advance the technology and to accelerate its systematic application in basic biomedical research and drug discovery."
RNAi is a natural cellular process that is involved in the regulation of gene expression. In recent years scientists have developed methods that allow RNAi to be exploited as a research tool to decipher the function of particular genes. The goal of the consortium is to create widely applicable RNAi research reagents that will enable biomedical researchers to discover the key genes underlying normal physiology as well as disease states. It is widely believed that RNAi will revolutionize the way in which life science research is conducted and is expected to have a major impact on the understanding of the genetic basis of diseases such as cancer, arthritis and Alzheimer's.
Novartis and Gen-Probe Agree to Extend and Expand Blood Screening Collaboration
Chiron, a Novartis business, announced that it has agreed to extend and expand its blood screening collaboration with Gen-Probe until 2025. The companies will continue to work together to develop and commercialize molecular technologies that safeguard the world's donated blood supply. The ... more
Novartis and Lonza have entered into a long term strategic partnership for the joint development and manufacture of the Novartis biological pipeline. Lonza will contribute its biotech leadership knowledge in process development and the manufacturing of complex processes to the collaboration ... more
Innogenetics concludes settlement and licensing agreement in the field of Hepatitis C diagnostics
Innogenetics announced an agreement with Novartis on major licensing terms in the field of Hepatitis C Virus (HCV) diagnostics. According to the license agreement, Novartis grants Innogenetics a license to its Hepatitis C patent rights in the field of HCV immunodiagnostics in certain territ ... more
Sigma® Life Science and King's College London co-developing miRNA Target Identification Technology
Sigma Life Science of Sigma-Aldrich® and King’s College London announced an exclusive license to develop and commercialize new technology for the identification and validation of microRNA (miRNA) targets in research and clinical diagnostics. miRNAs function as critical regulators of gene ex ... more
Sigma-Aldrich Acquires ChemNavigator, Inc.
Sigma-Aldrich announced the acquisition of cheminformatics company, ChemNavigator .com, Incorporated, a provider of discovery research informatics software tools used for design, selection and procurement of chemical compound libraries. The acquisition links ChemNavigator's suite of virtual ... more
Sigma-Aldrich announced that BioInformatics, LLC, reports that the Company's online product catalog is considered by scientists to be "most useful" and "easiest to use". "Our catalog team represents the long-term commitment of some of our most experienced scientists and talented publicatio ... more
454 Life Sciences and Roche NimbleGen Announce Collaboration with Eli Lilly and SeqWright
454 Life Sciences, a Roche company, and Roche NimbleGen, both units of Roche Applied Science, have announced a collaboration with Eli Lilly and Company and SeqWright. The goal of this collaboration is to use genomic technologies to identify genetic variants possibly associated with various ... more
Chemists synthesize herbal alkaloid
The club moss Lycopodium serratum is a creeping, flowerless plant used in homeopathic medicine to treat a wide variety of ailments. It contains a potent brew of alkaloids that have attracted considerable scientific and medical interest. However, the plant makes many of these compounds in ex ... more
Sigma-Aldrich Joins RNAi Consortium
Sigma-Aldrich Corporation has entered into an agreement with the Massachusetts Institute of Technology (MIT) to serve as a scientific collaborator and distribution partner of The RNAi Consortium (TRC). The consortium is based at The Broad Institute in Boston and is comprised of seven world- ... more
Cornell: Project aims to sequence 2,500 genomes
Cornell researchers are part of an international collaboration to build the most detailed map of human genetic variation. The map promises to provide a much more comprehensive understanding of the role of inherited DNA variation in human history, evolution and disease and the best methods t ... more
Genetic 'roadmap' charts links between drugs and human disease
A research team led by scientists at the Broad Institute of MIT and Harvard announced the development of a new kind of genetic "roadmap" that can connect human diseases with potential drugs to treat them, as well as predict how new drugs work in human cells. Called the "Connectivity Map," t ... more
Sigma-Aldrich Joins RNAi Consortium
Sigma-Aldrich Corporation has entered into an agreement with the Massachusetts Institute of Technology (MIT) to serve as a scientific collaborator and distribution partner of The RNAi Consortium (TRC). The consortium is based at The Broad Institute in Boston and is comprised of seven world- ... more
About analytica-world.com
analytica-world.com is the industry portal of the international trade fair analytica, which is organized by Messe München. It features useful information about markets, trends and innovations. It is operated by CHEMIE.DE, one of analytica's official sales partners.
Advertising at analytica-world.com
Our advertising formats support you in getting your message across to a clearly defined target audience.
The global network of analytica trade fairs:
